Transthyretin, or ATTR, amyloidosis is a rare disease that, if left untreated, can be devasting and fatal to the patient. Fortunately, in the past decade, there have been advancements in specialized therapies targeting this disease that can improve both quality of life and survival. The Advanced Heart and Lung Disease Center at Baylor Scott & White All Saints Medical Center – Fort Worth is one of the first heart centers in Tarrant County to use Vutisiran (administered under the name of Amvuttra), a small inhibiting RNA silencer that targets the transthyretin protein transcription pathway, to treat the condition. Salman Gohar, MD, FACC, medical director of advanced heart failure and mechanical circulatory support at Baylor Scott & White – Fort Worth and Baylor Scott & White Heart and Vascular Hospital – Fort Worth, is on a mission to help physicians identify this disease early, approaching diagnosis through a new lens.